These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20442528)

  • 1. Bortezomib-induced acute pancreatitis.
    Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
    JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
    [No Abstract]   [Full Text] [Related]  

  • 2. Is bortezomib a rare cause of acute pancreatitis?
    Solakoglu T; Akar M; Aktan Kosker T; Buyukasik S; Ersoy O
    JOP; 2013 Nov; 14(6):682-3. PubMed ID: 24216563
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute pancreatitis caused by bortezomib.
    Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
    Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Dun X; Yuan Z; Fu W; Zhang C; Hou J
    Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 7. Deafness associated with the use of Bortezomib in multiple myeloma.
    Chim CS; Wong LG
    Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
    Connolly G
    Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
    [No Abstract]   [Full Text] [Related]  

  • 11. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 13. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
    Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
    Mangiacavalli S; Corso A; De Amici M; Varettoni M; Alfonsi E; Lozza A; Lazzarino M
    Br J Haematol; 2010 Jun; 149(6):916-8. PubMed ID: 20201942
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    Duek A; Feldberg E; Haran M; Berrebi A
    Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 20. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
    Yokose N; Hirakawa T; Inokuchi K
    Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.